Treatment of acute idiopathic thrombocytopenic purpura in children. A retrospective evaluation of 120 cases

Carlo Baronci, Angelamaria Petrone, Crescenzo Miano, Alessandra Lombardi, Maurizio Caniglia, Lidia Angiolina Russo, Matteo Luciani, Rita Maria Pinto, Ippolita Rana, Roberta Caruso, Giulio De Rossi

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Acute idiopathic thrombocytopenic purpura (AITP) in children is generally a benign disease with a high frequency of spontaneous remission. Nevertheless the debate over treating or not is still open, because of the high risk of hemorrhage as long as the platelet count remains below 20 x 109/l. We have retrospectively evaluated 120 pediatric cases from our center, receiving different treatments at diagnosis: no treatment (76); IVIG: 400 mg/kg/d for 5 days (28); continuous oral PDN: 1-1.5 mg/kg/d for at least two weeks (16). No patients had been previously treated for AITP. Follow-up is up to fifty months. We found no significant differences as to the percentage of responses among the three groups. We conclude that waiting without treatment is safe and appropriate in most cases; whether the hemorrhagic risk suggests treatment, standard dose continuous oral PDN and IVIG may be equally effective, but IVIG may achieve a significantly faster rise in the platelet count. The timing of treatment and the cost/benefit ratio are discussed.

Original languageEnglish
Pages (from-to)457-461
Number of pages5
JournalAnnali dell'Istituto Superiore di Sanita
Volume34
Issue number4
Publication statusPublished - 1998

Fingerprint

Idiopathic Thrombocytopenic Purpura
Intravenous Immunoglobulins
Platelet Count
Spontaneous Remission
Therapeutics
Health Care Costs
Cost-Benefit Analysis
Pediatrics
Hemorrhage

Keywords

  • Immune thrombocytopenic purpura
  • Immunoglobulins
  • Steroid

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Baronci, C., Petrone, A., Miano, C., Lombardi, A., Caniglia, M., Russo, L. A., ... De Rossi, G. (1998). Treatment of acute idiopathic thrombocytopenic purpura in children. A retrospective evaluation of 120 cases. Annali dell'Istituto Superiore di Sanita, 34(4), 457-461.

Treatment of acute idiopathic thrombocytopenic purpura in children. A retrospective evaluation of 120 cases. / Baronci, Carlo; Petrone, Angelamaria; Miano, Crescenzo; Lombardi, Alessandra; Caniglia, Maurizio; Russo, Lidia Angiolina; Luciani, Matteo; Pinto, Rita Maria; Rana, Ippolita; Caruso, Roberta; De Rossi, Giulio.

In: Annali dell'Istituto Superiore di Sanita, Vol. 34, No. 4, 1998, p. 457-461.

Research output: Contribution to journalArticle

Baronci, C, Petrone, A, Miano, C, Lombardi, A, Caniglia, M, Russo, LA, Luciani, M, Pinto, RM, Rana, I, Caruso, R & De Rossi, G 1998, 'Treatment of acute idiopathic thrombocytopenic purpura in children. A retrospective evaluation of 120 cases', Annali dell'Istituto Superiore di Sanita, vol. 34, no. 4, pp. 457-461.
Baronci, Carlo ; Petrone, Angelamaria ; Miano, Crescenzo ; Lombardi, Alessandra ; Caniglia, Maurizio ; Russo, Lidia Angiolina ; Luciani, Matteo ; Pinto, Rita Maria ; Rana, Ippolita ; Caruso, Roberta ; De Rossi, Giulio. / Treatment of acute idiopathic thrombocytopenic purpura in children. A retrospective evaluation of 120 cases. In: Annali dell'Istituto Superiore di Sanita. 1998 ; Vol. 34, No. 4. pp. 457-461.
@article{4732fa104bc14fa68ec10332e5b854a1,
title = "Treatment of acute idiopathic thrombocytopenic purpura in children. A retrospective evaluation of 120 cases",
abstract = "Acute idiopathic thrombocytopenic purpura (AITP) in children is generally a benign disease with a high frequency of spontaneous remission. Nevertheless the debate over treating or not is still open, because of the high risk of hemorrhage as long as the platelet count remains below 20 x 109/l. We have retrospectively evaluated 120 pediatric cases from our center, receiving different treatments at diagnosis: no treatment (76); IVIG: 400 mg/kg/d for 5 days (28); continuous oral PDN: 1-1.5 mg/kg/d for at least two weeks (16). No patients had been previously treated for AITP. Follow-up is up to fifty months. We found no significant differences as to the percentage of responses among the three groups. We conclude that waiting without treatment is safe and appropriate in most cases; whether the hemorrhagic risk suggests treatment, standard dose continuous oral PDN and IVIG may be equally effective, but IVIG may achieve a significantly faster rise in the platelet count. The timing of treatment and the cost/benefit ratio are discussed.",
keywords = "Immune thrombocytopenic purpura, Immunoglobulins, Steroid",
author = "Carlo Baronci and Angelamaria Petrone and Crescenzo Miano and Alessandra Lombardi and Maurizio Caniglia and Russo, {Lidia Angiolina} and Matteo Luciani and Pinto, {Rita Maria} and Ippolita Rana and Roberta Caruso and {De Rossi}, Giulio",
year = "1998",
language = "English",
volume = "34",
pages = "457--461",
journal = "Annali dell'Istituto Superiore di Sanita",
issn = "0021-2571",
publisher = "Istituto Superiore di Sanita",
number = "4",

}

TY - JOUR

T1 - Treatment of acute idiopathic thrombocytopenic purpura in children. A retrospective evaluation of 120 cases

AU - Baronci, Carlo

AU - Petrone, Angelamaria

AU - Miano, Crescenzo

AU - Lombardi, Alessandra

AU - Caniglia, Maurizio

AU - Russo, Lidia Angiolina

AU - Luciani, Matteo

AU - Pinto, Rita Maria

AU - Rana, Ippolita

AU - Caruso, Roberta

AU - De Rossi, Giulio

PY - 1998

Y1 - 1998

N2 - Acute idiopathic thrombocytopenic purpura (AITP) in children is generally a benign disease with a high frequency of spontaneous remission. Nevertheless the debate over treating or not is still open, because of the high risk of hemorrhage as long as the platelet count remains below 20 x 109/l. We have retrospectively evaluated 120 pediatric cases from our center, receiving different treatments at diagnosis: no treatment (76); IVIG: 400 mg/kg/d for 5 days (28); continuous oral PDN: 1-1.5 mg/kg/d for at least two weeks (16). No patients had been previously treated for AITP. Follow-up is up to fifty months. We found no significant differences as to the percentage of responses among the three groups. We conclude that waiting without treatment is safe and appropriate in most cases; whether the hemorrhagic risk suggests treatment, standard dose continuous oral PDN and IVIG may be equally effective, but IVIG may achieve a significantly faster rise in the platelet count. The timing of treatment and the cost/benefit ratio are discussed.

AB - Acute idiopathic thrombocytopenic purpura (AITP) in children is generally a benign disease with a high frequency of spontaneous remission. Nevertheless the debate over treating or not is still open, because of the high risk of hemorrhage as long as the platelet count remains below 20 x 109/l. We have retrospectively evaluated 120 pediatric cases from our center, receiving different treatments at diagnosis: no treatment (76); IVIG: 400 mg/kg/d for 5 days (28); continuous oral PDN: 1-1.5 mg/kg/d for at least two weeks (16). No patients had been previously treated for AITP. Follow-up is up to fifty months. We found no significant differences as to the percentage of responses among the three groups. We conclude that waiting without treatment is safe and appropriate in most cases; whether the hemorrhagic risk suggests treatment, standard dose continuous oral PDN and IVIG may be equally effective, but IVIG may achieve a significantly faster rise in the platelet count. The timing of treatment and the cost/benefit ratio are discussed.

KW - Immune thrombocytopenic purpura

KW - Immunoglobulins

KW - Steroid

UR - http://www.scopus.com/inward/record.url?scp=0032424821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032424821&partnerID=8YFLogxK

M3 - Article

VL - 34

SP - 457

EP - 461

JO - Annali dell'Istituto Superiore di Sanita

JF - Annali dell'Istituto Superiore di Sanita

SN - 0021-2571

IS - 4

ER -